EWTX Live signals | Maximize Profits with Getagraph.com

BUY 89423 min ago

@ $18.60

Issued: 14 Feb 2024 @ 12:04

Return: -9.44%

Previous signal: Feb 13 - 14:56

Previous signal: Sell

Return: 2.65 %

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 15:25):

Stats
Today's Volume	322 637
Average Volume	946 708
Market Cap	1.57B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.390 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.73
ATR14	$0.0270 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-07	Moore John R	Sell	17 993	Stock Option (Right to Buy)
2024-02-08	Moore John R	Sell	3 813	Stock Option (Right to Buy)
2024-02-09	Moore John R	Sell	8 029	Stock Option (Right to Buy)
2024-02-07	Moore John R	Buy	17 993	Common Stock
2024-02-09	Moore John R	Buy	8 029	Common Stock

INSIDER POWER
74.55
Last 97 transactions
Buy: 6 997 164 \| Sell: 659 479

Volume Correlation

Long: 0.14 (neutral)

Short: -0.87 (strong negative)

Signal:(59.075) Neutral

Edgewise Therapeutics, Correlation

10 Most Positive Correlations
TLGT	0.915
SRTS	0.909
SYBX	0.897
PAIC	0.897
SVAC	0.896
CNDT	0.895
APOP	0.887
FULC	0.883
ATHA	0.875
CPIX	0.875

10 Most Negative Correlations
MMAC	-0.947
NETE	-0.928
BOCH	-0.906
AMRB	-0.901
NRDS	-0.886
SOFIW	-0.878
EPZM	-0.873
VCTR	-0.869
SHSP	-0.868
CNCE	-0.865

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Edgewise Therapeutics, Correlation - Currency/Commodity

0.79
( moderate )

0.75
( moderate )

0.00
( neutral )

0.77
( moderate )

-0.76
( moderate negative )

-0.85
( strong negative )

Edgewise Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.73M (0.00 %)
EPS:	$-1.570

Q4	2023
Revenue:	$0
Gross Profit:	$-533 000 (0.00 %)
EPS:	$-0.470

Q3	2023
Revenue:	$0
Gross Profit:	$-448 000 (0.00 %)
EPS:	$-0.410

Q2	2023
Revenue:	$0
Gross Profit:	$-437 000 (0.00 %)
EPS:	$-0.340

Financial Reports:

No articles found.

Edgewise Therapeutics,

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.